Pathmaker Bio offers a patented Conversomes™ platform that creates synthetic affinity reagents—"synthetic antibodies"—capable of recognizing individual amino acids and their post‑translational modifications.
Funding
Funding not disclosed
Founders
Product
Problem
Accurate detection of protein and peptide biomarkers often relies on antibodies, which can be costly to develop, may lack specificity for post‑translational modifications, and are not easily scalable for custom panels.
Solution
Pathmaker Bio addresses this gap with its patented Conversomes™ technology, which creates synthetic affinity reagents that selectively bind individual amino acids and their post‑translational modifications. These reagents act as “synthetic antibodies,” enabling quantitative measurement of custom protein or peptide panels. The workflow integrates with standard benchtop DNA analysis platforms such as quantitative PCR and next‑generation sequencing, allowing laboratories to perform on‑demand biomarker assays without specialized equipment. By leveraging DNA‑based readouts, the system provides high multiplexing capability and rapid assay development for disease diagnostics and monitoring.
Target Audience
Primary customers are clinical diagnostics laboratories, biotech research teams, and pharmaceutical companies that require precise, customizable protein/peptide biomarker assays.
Features
- Conversomes™ molecules engineered to recognize specific amino acids and PTMs with high specificity
- Ability to generate custom affinity reagents for any target protein, peptide, or biomarker region
- Compatibility with widely used DNA analysis tools (qPCR, NGS) for quantitative readout
- Scalable, multiplexed assay format supporting large biomarker panels
- Streamlined benchtop workflow that eliminates the need for traditional antibody production